Advanced search
Publication Cover
mAbs Volume 13, 2021 - Issue 1
Submit an article Journal homepage
8,717
Views
11
CrossRef citations to date
0
Altmetric
Report

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries

Andre Azevedo Reis Teixeiraa New Mexico Consortium, Los Alamos, NM, USAORCID Iconhttps://orcid.org/0000-0002-8348-0235View further author information
ORCID Icon,
Michael Frank Erasmusb Specifica Inc, Santa Fe, NM, USAORCID Iconhttps://orcid.org/0000-0002-8046-5048View further author information
ORCID Icon,
Sara D’Angelob Specifica Inc, Santa Fe, NM, USAORCID Iconhttps://orcid.org/0000-0002-8329-9938View further author information
ORCID Icon,
Leslie Naranjob Specifica Inc, Santa Fe, NM, USAORCID Iconhttps://orcid.org/0000-0003-2165-0814View further author information
ORCID Icon,
Fortunato Ferrarab Specifica Inc, Santa Fe, NM, USAORCID Iconhttps://orcid.org/0000-0002-4615-035XView further author information
ORCID Icon,
Camila Leal-Lopesa New Mexico Consortium, Los Alamos, NM, USAORCID Iconhttps://orcid.org/0000-0001-7058-3350View further author information
ORCID Icon,
Oliver Durrantc UCB Pharma Ltd, Slough, UKORCID Iconhttps://orcid.org/0000-0003-3183-7025View further author information
ORCID Icon,
Cecile Galmichec UCB Pharma Ltd, Slough, UKORCID Iconhttps://orcid.org/0000-0002-4866-0484View further author information
ORCID Icon,
Aleardo Morellic UCB Pharma Ltd, Slough, UKView further author information
,
Anthony Scott-Tuckerc UCB Pharma Ltd, Slough, UKView further author information
&
Andrew Raymon Morton Bradburyb Specifica Inc, Santa Fe, NM, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5567-8172View further author information
ORCID Icon show all
Article: 1980942 | Received 30 Jun 2021, Accepted 10 Sep 2021, Published online: 01 Dec 2021

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Paul Arras, Han Byul Yoo, Lukas Pekar, Christian Schröter, Thomas Clarke, Simon Krah, Daniel Klewinghaus, Vanessa Siegmund, Andreas Evers & Stefan Zielonka. (2023) A library approach for the de novo high-throughput isolation of humanized VHH domains with favorable developability properties following camelid immunization. mAbs 15:1.
Read now
Yang Zhang. (2023) Evolution of phage display libraries for therapeutic antibody discovery. mAbs 15:1.
Read now
Hristo L. Svilenov, Paolo Arosio, Tim Menzen, Peter Tessier & Pietro Sormanni. (2023) Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties. mAbs 15:1.
Read now
Fortunato Ferrara, Sara D’Angelo, M. Frank Erasmus, André A. Teixeira, Camila Leal-Lopes, Laura P. Spector, Tom Pohl, Adeline Fanni, Simon Cocklin & Andrew R. M. Bradbury. (2022) Pandemic’s silver lining. mAbs 14:1.
Read now
Andre A. R. Teixeira, Sara D’Angelo, M. Frank Erasmus, Camila Leal-Lopes, Fortunato Ferrara, Laura P. Spector, Leslie Naranjo, Esteban Molina, Tamara Max, Ashley DeAguero, Katherine Perea, Shaun Stewart, Rebecca A. Buonpane, Horacio G. Nastri & Andrew R. M. Bradbury. (2022) Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs. mAbs 14:1.
Read now

Articles from other publishers (6)

Angelo Rosace, Anja Bennett, Marc Oeller, Mie M. Mortensen, Laila Sakhnini, Nikolai Lorenzen, Christian Poulsen & Pietro Sormanni. (2023) Automated optimisation of solubility and conformational stability of antibodies and proteins. Nature Communications 14:1.
Crossref
Nileena Velappan, Fortunato Ferrara, Sara D’Angelo, Devin Close, Leslie Naranjo, Madeline R. Bolding, Sarah C. Mozden, Camille B. Troup, Donna K. McCullough, Analyssa Gomez, Marijo Kedge & Andrew R. M. Bradbury. (2023) Direct selection of functional fluorescent-protein antibody fusions by yeast display. PLOS ONE 18:2, pages e0280930.
Crossref
Mohammad Yasir, Alok Shiomurti Tripathi, Prashant Shukla & Rahul Kumar Maurya. 2023. Protein-based Therapeutics. Protein-based Therapeutics 251 273 .
Alain Beck, Christine Nowak, Deborah Meshulam, Kristina Reynolds, David Chen, Dennis B. Pacardo, Samantha B. Nicholls, Gregory J. Carven, Zhenyu Gu, Jing Fang, Dongdong Wang, Amit Katiyar, Tao Xiang & Hongcheng Liu. (2022) Risk-Based Control Strategies of Recombinant Monoclonal Antibody Charge Variants. Antibodies 11:4, pages 73.
Crossref
Bharathikumar Vellalore Maruthachalam, Kris Barreto, Daniel Hogan, Anthony Kusalik & Clarence Ronald Geyer. (2022) Generation of synthetic antibody fragments with optimal complementarity determining region lengths for Notch-1 recognition. Frontiers in Microbiology 13.
Crossref
Fortunato Ferrara, M. Frank Erasmus, Sara D’Angelo, Camila Leal-Lopes, André A. Teixeira, Alok Choudhary, William Honnen, David Calianese, Deli Huang, Linghan Peng, James E. Voss, David Nemazee, Dennis R. Burton, Abraham Pinter & Andrew R. M. Bradbury. (2022) A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. Nature Communications 13:1.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.